|Scientific Project Portfolio Management

Tunnell Government Services (TGS) employees provide holistic, tailorable project and program management (PM) services in support of our government clients. Each client is unique and, in some cases, even projects with the same client may differ. As a consequence, this demands flexible management practices to enable data-driven decision-making. For instance, our government customers who support FDA-regulated medical product development require an adaptive approach for product management as candidate therapeutics/diagnostics/biologics matriculate through discovery, clinical trials and post-marketing surveillance studies. We work side-by-side with our government partners with the development of metrics and cost estimates that measure the progress against interim and final objectives and ensure that clients are in a position to make well-informed decisions.

♦ Full spectrum support in the form of phase of development; tech base, animal, clinical, and manufacturing phase

♦ Full spectrum in the form of products; biologics, drugs, and devices

♦ Full spectrum in the support services; biomedical sciences, regulatory and quality assurance, manufacturing, clinical affairs, logistical, biostatistical analysis, budget estimating and financial controls, project management

♦ Full spectrum in the form of individual project management at a tactical level to a portfolio of projects at the strategic level

Our ability to provide these quality management services is enhanced by our adherence and adoption of industry best practices for optimal management of complex, multifaceted scientific and research practices. TGS’s infusion of new methods for more effective and efficient management is in part due to our ability to “reach back” into our corporation’s intimate relationships and understanding of the pharmaceutical industry. Although not all industrial practices are well-suited to the public service domain, we are uniquely positioned to tailor those industry practices and keep our government clients aware of deviations to schedule, cost, performance and quality.

More importantly, with regard to medical product development within the DoD, we have extensive experience in navigating the regulatory and the acquisition management processes. Although these program processes run concurrently, they are not synchronous and, as a result, can create unexpected turbulence in the execution of programs. We have the depth of experience to minimize the disruptive influences that increase the administrative risk associated with medical product failure.

Reference Materials

Integrated Sustainable Solutions
Operational Excellence
Technology Transfer by Design
Six Sigma and Lean

Press

Jens H. Kuhn, Ph.D., Contributes to Article on ``Taxonomy of the Order Mononegavirales: Update 2017``
Jens H. Kuhn, Ph.D., Contributes to Article on “Taxonomy of the Order Mononegavirales:  Update 2017”.

07/24/2017

 

View Abstract

Jens H. Kuhn, Ph.D., Contributes to Research Paper on Crimean-Congo Hemorrhagic Fever
Jens H. Kuhn, Ph.D., Contributes to Research Paper on Crimean-Congo Hemorrhagic Fever

06/01/2011

A research paper about Crimean-Congo hemorrhagic fever is now available via ScienceDirect. Jens H. Kuhn, of Tunnell Government Services, is a contributing author.  Purchase the article to find out more about the development of prophylaxis and therapy for CCHF and discuss future prospects for vaccine and drug development.

View Abstract

Yingyun Cai, Ph.D., Provides Insight on an Immunotoxin Targeting the gH Glycoprotein of KSHV 06/30/2011
Yingyun Cai, Ph.D., Provides Insight on an Immunotoxin Targeting the gH Glycoprotein of KSHV

06/30/2011

Tunnell Government Services, Inc. contributor Yingyun Cai shared in-depth research in a recent study on an immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.  These findings suggest that selective killing of virus-producing cells might represent a novel therapeutic strategy.  To find out more, read the entire abstract and purchase the study via ScienceDirect.

View Abstract

Julie Dyall, Ph.D. and Catherine Jett, MPH Participate in Comparative Analysis of the Monkeypox Virus Infection
Julie Dyall, Ph.D. and Catherine Jett, MPH Participate in Comparative Analysis of the Monkeypox Virus Infection

02/06/2012

Tunnell Government Services consultants Julie Dyall, Ph.D. and Catherine Jett, MPH,  were two of the co-authors of a recent article that investigated the geographic expansion of the Monkeypox virus and its fatal potential.  They studied various forms of inoculations with the goal of determining the best form of treatment for nonhuman primates. Please click below to see the results of their investigation.

View Abstract

|Contact Us

For more about our company, products or services.

Contact Us»